NAPSRX CNPR EXAM | QUESTIONS WITH 100% CORRECT 960 ANSWERS (REVISED 18TH EDITION) |VERIFIED | UPDATED, NAPSRX / CNPR EXAM NEWEST VERSION 2026/2027 GRADED A+, NAPSRX CNPR EXAM: KEY CONCEPTS AND QUESTIONS WITH 100% CORRECT ANSWERS | VERIFIED | LATES

NAPSRX CNPR EXAM | QUESTIONS
WITH 100% CORRECT 960 ANSWERS
(REVISED 18TH EDITION) |VERIFIED |
UPDATED, NAPSRX / CNPR EXAM
NEWEST VERSION 2026/2027
GRADED A+, NAPSRX CNPR EXAM:
KEY CONCEPTS AND QUESTIONS
WITH 100% CORRECT ANSWERS |
VERIFIED | LATEST UPDATED
1. whatmdoesmamSTATmordermmean?m-
mCORRECTmANSWERmamdrugmneededmimmediatelymandmgivenmonlymonce




2. whatminformationmdoesmthemoverdosagemsectionmofmthemlabelingmprovide?m-
mCORRECTmANSWERmsigns,msymptomsmandmtreatmentmofmacutemoverdoses




3. typesmofmdrug-drugminteractions:m-
mCORRECTmANSWERmduplication,moppositionm(antagonism)mandmalterationm(p.51)




4. tolerancemvsmresistancem-
mCORRECTmANSWERmtolerancemismthemdiminishedmresponsemtomamdrug;mresistancemismthem


cellsmabilitymtomresistmthemeffectsmofmthemdrugmonmthem.



5. abbreviatedmnewmdrugmapplicationm(ANDA)m-
mCORRECTmANSWERmthemprocessmbymwhichmapplicantsmmustmscientificallymdemonstratemt


omthemFDAmthatmtheirmgenericmproductmismbioequivalentmtomormperformsminmthemsamemway
masmtheminnovatormdrug,mnomduplicatemtestingm(p.m75)

,6. themHatch-WaxmanmActmofm1984m-mCORRECTmANSWERm-
A.K.A.mDrugmPricemCompetitionmandmPatentmRestorationmAct
7. -
mademitmeasiermtombringmgenericmdrugsmtomthemmarketmbymrequiringmthemFDAmtomonlymlook
matmbioavailabilitymstudiesminmordermtomapprovemanmANDA.


8. -gavemprotectionmtomthemresearchmbasedmmanufacturersmbymprovidingmam30-
monthmautomaticmcoolingmoffmperiodmoncemanmANDAmismchallengedmformpatentminfringem
entm(p.m75)



9. fourmbasicmtransportmmechanismsm-
mCORRECTmANSWERmpassivemdiffusion,mfacilitatedmdiffusion,mactivemtransport,mandmpinoc


ytosism(p.m95)



10. potencymvsmefficacym-
mCORRECTmANSWERmpotency:mamountmofmdrugmnecessarymtomproducemdesiredmeffect


11. efficacy:mmagnitudemofmmaximalmresponsemthatmcanmbemreceivedmfrommamdrug
12. *efficacymismalmostmalwaysmmoremimportantmthatmpotency*m(p.m106)



13. themfourmphasesmofmclinicalmtrialsm-mCORRECTmANSWERmphasesmI-IVm(P.m124-126)



14. KeymPartsmOfmAmClinicalmPaperm(5)m-
mCORRECTmANSWERmAbstract,mIntroduction,mmethods,mresults,mdiscussion/conclusionsm(p


.m128-129)



15. reliabilitymvsmvaliditym-
mCORRECTmANSWERmreliabilitym=mconsistencymandmvaliditym=maccuracy


16. (p.m138;m143)



17. samplingmerrormvsmselectionmbiasm-
mCORRECTmANSWERmsamplingmerrormismunbiasedmandmismrandomlymchosenmfrommthempop


ulation.m

,18. selectionmbiasmismwhenmthemsamplemwasmspecificallymchosenmbasedmonmparticularmcharact
eristicsm(p.142-143)



19. independentmvsmdependentmvariablem-
mCORRECTmANSWERmAnmindependentmvariablemismthemonemthatminfluencesmthemvariation.m


Amdependentmvariablemismthemvariablembeingmtestedmandmmeasuredminmamscientificmexperi
mentm(themresultmofmapplyingmthemindependentmvariable).



20. DrugmUtilizationmReviewm(DUR)mprogramsm-mCORRECTmANSWERm-
involvemretrospectivemmonitoringmofmphysicians'mprescribingmpatterns
21. -moremthanm90%mofmHMOsmrequiremDURs
22. -nowadaysmmostlymmonitorsmcostmsavingsm(p.m181)



23. opportunitymcostm-
mCORRECTmANSWERmbasedmonmthempremisemthatmallmresourcesmaremscarce,mandmtherefore


meverymtimemwemchoosemtomusemamresourcemitmreducesmthempossibilitymofmitmbeingmusedminm


anothermway.



24. whatmtypemofmDTCmadvertisingmismthemonlymlegalmformminmEurope?m-
mCORRECTmANSWERmDisease-


statemormunbrandedmadsm(providesmpublicminformationmonmamdisease,mnotmamdrug)
25. (p.m223)



26. canmpharmmsalesmrepsmoffermdoctorsmmeals?m(PhRMAmcode)m-
mCORRECTmANSWERmcompanymrepsmcanmonlymoffermoccasionalmmealsmasmlongmasmtheymare


mmodest,mandmonlymofferedminmanmoffice/hospitalmsettingminmconjunctionmwithmanmeducati


onalmpresentation.m(p.m228)



27. FAQmaboutmthemPhRMAmcodem-mCORRECTmANSWERmp.m268-274



28. UrologymandmsellingmtomUrologistsm-mCORRECTmANSWERmp.m300-301

, 29. whatmismamMedicalmSciencemLiaisonm(MLS)?m-
mCORRECTmANSWERmtheymservemasmeducatorsmandmfield-


basedmmedicalmresources.mtheyminterfacembetweenmtheirmcompanymandmhealthcaremleade
rs.



30. pushmthroughmvsmpullmthroughmsalesmstrategiesm-mCORRECTmANSWERm-mpush-
throughmrefersmtomthemcompany'smoverallmeffortsmtomdemonstratemclinicalmefficiencymandm
efficacymandmcostmeffectivenessmofmamproduct.m
- pull-
throughmgeneratesmdemandmformthemproduct,musuallyminmwaysmconsistentmwithmth
emhealthmplansmgoalsmandmguidelines.m(p.m311)



31. drugmlabelingmrequirementsmFDAm-mCORRECTmANSWERmhttps://www.fda.gov/about-
fda/oncology-center-excellence/how-do-i-use-prescription-drug-labeling#Section-10



32. Whatmismpredictivemvalidity?m-
mCORRECTmANSWERmthemabilitymofmanmindicatormtomcorrectlympredictmanmoutcome.




33. whatmaremsomemofmthemcriteriamthatminfluencemthemdecisionmtomusemmassmadvertisingminmp
harmaceuticalmmarketing?m-
mCORRECTmANSWERm*themsizemofmthemtargetmpatientmpopulation


34. themchronicitymofmthemdiseasemstate
35. themrelevancemofmthatmdiseasemstatemtomitsmsufferers
36. themavgmvaluemofmampatientmtakingmmedication



37. accordingmtomthemAMAmguidelines,mwhomshouldmacceptmsubsidiesmformcontinuingmmedical
meducationmconferences?m-mCORRECTmANSWERmconferencemsponsors




38. whomismthemdecisionmmakerminmpharmaceuticalmsales?m-
mCORRECTmANSWERmthemphysician